ReviewThrombosis journal2016
Vitamin K antagonist use: evidence of the difficulty of achieving and maintaining target INR range and subsequent consequences.
Review in Thrombosis journal, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 73 citations in OpenAlex.
- Patient Knowledge and Adherence to Oral Anticoagulation Therapy: Findings from an Observational Study in Italian Tertiary Care Hospitals.Patient preference and adherence · 2026Article
- Changes in quality of vitamin K antagonist treatment and clinical outcomes during Ramadan: a Dutch population-based cohort study.Research and practice in thrombosis and haemostasis · 2025Article
- Long-term left ventricular thrombosis resolution in patients receiving vitamin k antagonists: a multicenter observational study.Internal and emergency medicine · 2025Observational
- Determining Drug Exposure Based on Medication Dispensing Data: A Validation Study of Vitamin K Antagonist Treatment Episodes Against INR Records.Pharmacoepidemiology and drug safety · 2025Article
- Higher vitamin K1 intakes are associated with lower subclinical atherosclerosis and lower risk for atherosclerotic vascular disease-related outcomes in older women.European journal of nutrition · 2025Article
- Article
- Analysis of Personalized Cardiovascular Drug Therapy: From Monitoring Technologies to Data Integration and Future Perspectives.Biosensors · 2025Review
- Analysis of Postoperative Bleeding After Oral Surgery in Patients Receiving Anticoagulants: A Retrospective Study.Medicina (Kaunas, Lithuania) · 2025Article
- Time in the therapeutic range, bleeding event, and their determinants in older patients with atrial fibrillation on warfarin in Ethiopia: multicenter cross-sectional study.Frontiers in pharmacology · 2025Article
- Case Report: IVC-agenesis and FVL mutation; successful DVT/PE treatment with direct oral anticoagulation (factor Xa inhibitor).Frontiers in cardiovascular medicine · 2025Article
- A new strategy for monitoring of direct oral anticoagulants in patients with cyanotic and complex congenital heart disease.International journal of cardiology. Congenital heart disease · 2024Article
- Effect of a 3-Month Single-Drug Approach Using Rivaroxaban for Symptomatic Proximal Deep Vein Thrombosis.Circulation reports · 2024Article
- Maxillofacial haemorrhagic symptoms in emergency department patients: impact of antithrombotics.European journal of trauma and emergency surgery : official publication of the European Trauma Society · 2024Article
- Electrochemical Monitoring in Anticoagulation Therapy.Molecules (Basel, Switzerland) · 2024Review
- Oral Anticoagulants after Heart Transplantation-Comparison between Vitamin K Antagonists and Direct Oral Anticoagulants.Journal of clinical medicine · 2023Article
- Role of factor VIII, IX, and XI in venous thrombosis recurrence risk in adults and children: A systematic review.Research and practice in thrombosis and haemostasis · 2023Article
- A Real-World Cost-Effectiveness Analysis of Rivaroxaban versus Vitamin K Antagonists for the Treatment of Symptomatic Venous Thromboembolism: Lessons from the REMOTEV Registry.Medicina (Kaunas, Lithuania) · 2023Observational
- The Immediate Effect of COVID-19 Vaccination on Anticoagulation Control in Patients Using Vitamin K Antagonists.Thrombosis and haemostasis · 2022Article
- Stability of vitamin K antagonist anticoagulation after COVID-19 diagnosis.Research and practice in thrombosis and haemostasis · 2021Article
- Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research.Thrombosis and haemostasis · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vitamin K antagonists (VKAs) are effective oral anticoagulants that are titrated to a narrow therapeutic international normalized ratio (INR) range. We reviewed published literature assessing the impact of INR stability - getting into and staying in target INR range - on outcomes including thrombotic events, major bleeding, and treatment costs, as well as key factors that impact INR stability. A time in therapeutic range (TTR) of ≥65 % is commonly accepted as the definition of INR stability. In the real-world setting, this is seldom achieved with standard-of-care management, thus increasing the patients' risks of thrombotic or major bleeding events. There are many factors associated with poor INR control. Being treated in community settings, newly initiated on a VKA, younger in age, or nonadherent to therapy, as well as having polymorphisms of CYP2C9 or VKORC1, or multiple physical or mental co-morbid disease states have been associated with lower TTR. Clinical prediction tools are available, though they can only explain <10 % of the variance behind poor INR control. Clinicians caring for patients who require anticoagulation are encouraged to intensify diligence in INR management when using VKAs and to consider appropriate use of newer anticoagulants as a therapeutic option.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.